Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06872125 · ClinicalTrials.gov registry record · Phase 3
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
A Phase 3 study of Dravet Syndrome, sponsored by Stoke Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 170
- Enrollment target
- 20
- Study locations
NCT06872125: Recruiting Phase 3 study of Dravet Syndrome, sponsored by Stoke Therapeutics.
NCT06872125 is a Phase 3 study of Dravet Syndrome that is actively recruiting participants, run by Stoke Therapeutics. The registered enrollment target is 170 participants, above the 96-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (77% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06872125, a Phase 3 study of Dravet Syndrome, is actively recruiting participants, sponsored by Stoke Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 170 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
Primary Outcome
Measured by daily seizure diary
Conditions Studied
Interventions
- DRUG zorevunersen
- OTHER Sham Comparator
Study Locations (20)
California
- Cedars Sinai Medical Center - Los Angeles
- Children's Hospital of Orange County - Orange
- USCF Medical Center - San Francisco
Florida
- Nemours Children's Health - Jacksonville
- Nicklaus Children's Hospital - Miami
- Advent Health Neuroscience Research Institute - Orlando
New York
- NYU Langone Health - New York
- Weill Cornell Medicine - New York
- University of Rochester Medical Center - Rochester
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Children's Hospital - Boston
Arizona
- Phoenix Children's Hospital - Phoenix
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2025-06-04 |
| Est. Completion | 2028-10 |
| Phase | Phase 3 |
What NCT06872125 shows while recruiting
NCT06872125 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, above the 96-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (77% higher).
The record links to 1 condition, with Dravet Syndrome appearing as the primary indexed condition, and to 2 interventions - of which zorevunersen is the first listed.
NCT06872125 names 20 study sites across 13 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06872125 about?
NCT06872125 is a clinical study titled "A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome". The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
What is the current status of trial NCT06872125?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 170 participants. The study started on 2025-06-04. Estimated completion is 2028-10.
What conditions does trial NCT06872125 study?
This clinical trial studies the following conditions: Dravet Syndrome.
What interventions are being tested in trial NCT06872125?
The interventions under investigation include: zorevunersen (DRUG), Sham Comparator (OTHER).
Who is sponsoring clinical trial NCT06872125?
This trial is sponsored by Stoke Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06872125 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dravet Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06872125's enrollment target sits among peer trials
170 2nd of 12 the highest of 12 other Dravet Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dravet Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
RECRUITING · Phase 3
-
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
RECRUITING · Phase 3
-
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
RECRUITING · Phase 1
-
GABA Biomarkers in Dravet Syndrome
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI